53 results
Page 2 of 3
424B5
7cuh20z02csfu3xcp62j
11 Sep 20
Prospectus supplement for primary offering
4:44pm
8-K
EX-99.2
kcmkpqlnvfm014
9 Sep 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
5:26pm
424B5
0u6ov2
9 Sep 20
Prospectus supplement for primary offering
4:40pm
8-K
EX-99.1
cmt9h5iaos vw
10 Aug 20
Intra-cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7:52am
8-K
105y5e4
29 Jun 20
Intra-Cellular Therapies Announces PositiveTop-line Results fromITI-214 Phase I/II Study in Patients with Heart Failure
9:14am
8-K
EX-99.1
0841kljt8yjsl2ux
29 Jun 20
Intra-Cellular Therapies Announces PositiveTop-line Results fromITI-214 Phase I/II Study in Patients with Heart Failure
9:14am
8-K
EX-99.1
sq4h99ovit7db
7 May 20
Intra-cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
7:42am
8-K
EX-99.1
3d64zmr wsim2hcq09
23 Dec 19
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults
8:15am
8-K
EX-99.1
b6x60
6 Apr 16
Intra-Cellular Therapies Presents Additional ITI-007 Data at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference
12:00am